It usually takes several days to a week to get the results of cytochrome P450 tests. Once they're back, you and your doctor will discuss the results and how they might affect your treatment options.
CYP450 tests give clues to how well your body processes a drug by looking at specific enzymes. People can be classified according to how fast they metabolize medications. For example, results of a CYP2D6 test may show which of these four types applies to you:
- Poor metabolizers. If you process a certain drug more slowly than normal because of a missing enzyme, the medication can build up in your system. This can increase the likelihood that it will cause side effects. You might still be able to benefit from these medications, but at lower dosages.
- Intermediate metabolizers. If you have reduced enzyme function in processing drugs, you may not process some medications as well as normal metabolizers do. This can increase your risk of side effects and drug interactions.
- Normal metabolizers (also known as extensive metabolizers). If the test shows that you process certain antidepressants normally, you're more likely to benefit from treatment and have fewer side effects than people who don't process those particular medications as well.
- Ultrarapid metabolizers. In this case, medications leave your body too quickly — often before they have a chance to work properly. You'll likely need higher than usual doses of medications.
CYP450 testing isn't useful for all antidepressants, but it can provide information about how you're likely to process a number of them. For example:
- The CYP2D6 enzyme is involved in metabolizing antidepressants such as fluoxetine (Prozac), paroxetine (Paxil, Pexeva) and venlafaxine (Effexor XR), as well as tricyclic antidepressants such as nortriptyline (Pamelor), amitriptyline, clomipramine (Anafranil), desipramine (Norpramin) and imipramine (Tofranil). Some antidepressants, such as fluoxetine and paroxetine, can cause the CYP2D6 enzyme to slow down.
- The CYP2C19 enzyme is involved in metabolizing citalopram (Celexa) and escitalopram (Lexapro).
Although they have potential, CYP450 tests have limitations:
- Tests are available for only certain medications. Also, each test is specific to only one medication, so a change in medication may require another test.
- Testing can't predict for certain which particular medication will work best for you — it can only provide clues.
- Tests only look at some of the genes involved in how your body uses certain drugs — so factors out of the scope of the test may impact how an antidepressant will affect you.
- Tests focus on how the body metabolizes a drug, but not on what the drug does to the body, such as how the drug might change the brain receptors to improve symptoms.
- It isn't entirely clear how useful tests are in choosing an antidepressant. Even if you have tests, you may still need to try different antidepressants and different doses to identify what works best for you.
- Not all insurance companies cover the costs of these tests.
Despite the limitations, some doctors use CYP450 tests and think they're helpful. However, these tests aren't meant to be the only way to determine which antidepressants to try. They're just one tool that may help. Trying antidepressants based on your medical history and symptoms is still the standard method for identifying the best medication for your needs.
Aug. 21, 2015
- Hall-Flavin DK, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenetics and Genomics. 2013;23:535.
- Altar CA, et al. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. The Pharmacogenomics Journal. In press. Accessed July 13, 2015.
- Biernacka JM, et al. The International SSRI Pharmacogenomics Consortium (ISPC): A genome-wide association study of antidepressant treatment response. Translational Psychiatry. 2015;5:e533.
- Genetic testing — CYP450 genotyping to predict response to SSRIs used to treat non-psychotic depression in adults: EGAPP recommendation. Centers for Disease Control and Prevention. http://www.cdc.gov/genomics/gtesting/EGAPP/recommend/CYP450.htm. Accessed July 13, 2015.
- Genetic testing — General public: CYP450 genotyping and use of SSRI drugs for depression in adults. Centers for Disease Control and Prevention. http://www.cdc.gov/genomics/gtesting/EGAPP/recommend/CYP450_consumer.htm. Accessed July 13, 2015.
- Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clinical Chemistry. 2014;60:53.
- AskMayoExpert. Antidepressant medications and pharmacogenomics. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
- Samer CF, et al. Applications of CYP450 testing in the clinical setting. Molecular Diagnosis and Therapy. 2013;17:165.
- Tantisira K, et al. Overview of pharmacogenomics. http://www.uptodate.com/home. Accessed July 13, 2015.
- Steimer W. Pharmacogenetics and psychoactive drug therapy: Ready for the patient? Therapeutic Drug Monitoring. 2010;32:381.
- Mrazek DA, et al. Facilitating clinical implementation of pharmacogenomics. JAMA. 2011;306:304.
- Veldic M (expert opinion). Mayo Clinic, Rochester, Minn. Aug. 14, 2014.
- Kung S (expert opinion). Mayo Clinic, Rochester, Minn. July 23, 2015.